NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10811	Companies
234208	Keywords
162973	Articles
125192	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 05/21/2024 at 22:15, 2 years 2 months ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix announces progress in global NBTXR3 development collaboration, highlighting robust pipeline and pathway to long-term growth in cancer treatment. Updates include US FDA approvals and strategic study modifications

Cancer Treatment NANOBIOTIX NBTXR3 Global Development FDA Approvals
PRESS RELEASE

published on 05/21/2024 at 22:15, 2 years 2 months ago

Nanobiotix annonce des avancees de la collaboration globale de developpement autour de NBTXR3 refletant son pipeline robuste et son approche de croissance sur le long terme
Nanobiotix annonce des avancées de la collaboration globale de développement autour de NBTXR3 reflétant son pipeline robuste et son approche de croissance sur le long terme

Croissance À Long Terme NANOBIOTIX NBTXR3 Collaboration Globale Pipeline Robuste
BRIEF

published on 05/14/2024 at 22:20, 2 years 2 months ago

NANOBIOTIX Lance une Étude de Phase 2 sur le Traitement du Cancer du Poumon avec FDA Approval

FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
BRIEF

published on 05/14/2024 at 22:20, 2 years 2 months ago

NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval

FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
PRESS RELEASE

published on 05/14/2024 at 22:15, 2 years 2 months ago

NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois
Nanobiotix annonce l'acceptation par la FDA d'un protocole pour une nouvelle étude de phase 2 sur NBTXR3 pour le cancer du poumon de stade III

FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
PRESS RELEASE

published on 05/14/2024 at 22:15, 2 years 2 months ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients

Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol

Accesswire

Published on 08/07/2026 at 14:17, 1 hour 47 minutes ago

NuRAN Wireless Increases Series A Preferred Share Financing to C$7.6 Million and Announces Debt Settlements
Published on 08/07/2026 at 13:00, 3 hours 4 minutes ago

Gold Terra Announces Start of Drilling on the Campbell Shear Northern Zone 103N Extension to Expand 2026 MRE of Inferred 595,000 Ounces, Con Mine, Yellowknife, NWT
Published on 08/07/2026 at 00:45, 15 hours 19 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 16 hours 49 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 17 hours 49 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 15:39, 24 minutes ago

Predictiv AI Inc. Hires Aktien Media for Internet Advertising Services
Published on 08/07/2026 at 15:16, 47 minutes ago

Announcement pursuant to Art. 5 para 1 of Regulation (EU) No. 596/2014 in conjunction with Art. 2 para 1 of the Delegated Regulation (EU) 2016/1052 of the Commission
Published on 08/07/2026 at 15:06, 57 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/07/2026 at 15:05, 58 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 08/07/2026 at 15:04, 59 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

Les Echos

Published on 08/07/2026 at 15:36, 27 minutes ago

NRJ Group - Information relative aux droits de vote au 31.07.2026 (French & English)
Published on 08/07/2026 at 08:30, 7 hours 34 minutes ago

Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/07/2026 at 08:30, 7 hours 34 minutes ago

Déclaration nombre d'actions et droits de vote - 07.08.2026
Published on 08/06/2026 at 18:26, 21 hours 38 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 21 hours 38 minutes ago

Air Liquide droits de vote au 31 juillet 2026

View all LES ECHOS COMFI WIRE